Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study49
Impact of SF3B1 mutation in myelofibrosis44
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents30
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis28
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma26
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans25
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy23
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis22
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes22
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini21
Organ toxicities associated with chimeric antigen receptor T-cell therapy20
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia20
Hypereosinophilia after CAR T-cell therapy18
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation18
Transplantation provides superior survival high risk myeloid malignancies in older patients17
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax17
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma17
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)17
0.39093780517578